Bacteria: Gram-negative

Serratia marcescens

General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.

Overview

An environmental Gram-negative rod associated with healthcare outbreaks, catheters and contaminated solutions.

Infections

Urinary tract infection, pneumonia, bloodstream and wound infection, eye infection.

Signs and symptoms

Urinary infection in catheterized patients: fever and flank or suprapubic pain. Pneumonia in ventilated patients: fever and increased secretions. Bloodstream infection, sometimes traced to contaminated intravenous fluids or catheters: fever and chills. Eye infection in contact-lens wearers: a painful red eye with discharge. Some strains make a red pigment that can tint sputum.

Antibiotic and antimicrobial resistance

Chromosomal AmpC (AmpC); intrinsically resistant to nitrofurantoin and colistin.

Treatment considerations

Guided by susceptibility testing. IDSA guidance considers clinically significant AmpC induction less likely than with Enterobacter, so ceftriaxone can be used when the isolate tests susceptible. Serratia is intrinsically resistant to colistin and nitrofurantoin.

Infection control and public health

Clusters suggest a common environmental or device source.

Gram-negative rods, schematic
Gram-negative rods. Schematic, not to scale; InnovexLab.

Sources

  1. CDC. Healthcare-associated infections: diseases and organisms.
  2. CDC. ESBL-producing Enterobacterales.
  3. CDC. Carbapenem-resistant Enterobacterales (CRE).
  4. IDSA. Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
  5. IDSA. Complicated Urinary Tract Infections guideline.

Sources accessed November 2026. Links open external sites that InnovexLab does not control.

Medical disclaimer

This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.

Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.

Sources, image credits and editorial policy

Discuss a testing program with InnovexLab

Review the panel that fits your patients, its specimen requirements, and how results and billing work.